Outlook Therapeutics Overview
- Year Founded
-
2010

- Status
-
Public
- Employees
-
23

- Stock Symbol
-
OTLK

- Investments
-
1
- Share Price
-
$1.71
- (As of Friday Closing)
Outlook Therapeutics General Information
Description
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Contact Information
Website
www.outlooktherapeutics.comCorporate Office
- 111 South Wood Avenue
- Unit 100
- Iselin, NJ 08830
- United States
Corporate Office
- 111 South Wood Avenue
- Unit 100
- Iselin, NJ 08830
- United States
Outlook Therapeutics Timeline
Outlook Therapeutics Stock Performance
As of 07-Feb-2025, Outlook Therapeutics’s stock price is $1.71. Its current market cap is $54.7M with 24.9M shares.
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$1.71 | $1.73 | $0.87 - $12.85 | $54.7M | 24.9M | 2.11M | -$4.06 |
Outlook Therapeutics Financials Summary
As of 30-Sep-2024, Outlook Therapeutics has a trailing 12-month revenue of null.
In Thousands, USD |
TTM 30-Sep-2024 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 | FY 2022 30-Sep-2022 |
---|---|---|---|---|
EV | 127,021 | 127,021 | 58,545 | 260,394 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (72,999) | (72,999) | (57,376) | (64,357) |
Net Income | (75,367) | (75,367) | (58,983) | (66,052) |
Total Assets | 28,823 | 28,823 | 32,301 | 28,528 |
Total Debt | 29,738 | 29,738 | 35,555 | 10,958 |
Outlook Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Outlook Therapeutics Comparisons
Industry
Financing
Details
Outlook Therapeutics Competitors (30)
One of Outlook Therapeutics’s 30 competitors is Apellis Pharmaceuticals, a Formerly VC-backed company based in Waltham, MA.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Apellis Pharmaceuticals | Formerly VC-backed | Waltham, MA | ||||
Opthea | Corporation | South Yarra, Australia | ||||
Affimed | Formerly VC-backed | Mannheim, Germany | ||||
Henlius | Formerly VC-backed | Shanghai, China | ||||
Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Outlook Therapeutics Patents
Outlook Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210230261-A1 | Buffered formulations of bevacizumab for use of treating diseases | Inactive | 17-Apr-2018 | ||
EP-3781199-A1 | Buffered formulations of bevacizumab for use of treating diseases | Inactive | 17-Apr-2018 | ||
AU-2019256289-A1 | Buffered formulations of bevacizumab for use of treating diseases | Pending | 17-Apr-2018 | ||
CA-3097123-A1 | Buffered formulations of bevacizumab for use of treating diseases | Pending | 17-Apr-2018 | ||
EP-3411719-A1 | Methods for identifying and analyzing amino acid sequences of proteins | Inactive | 04-Feb-2016 | G01N33/6818 |
Outlook Therapeutics Signals
Outlook Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Outlook Therapeutics Investments (1)
Outlook Therapeutics’s most recent deal was a Joint Venture with Joint Venture (Outlook Therapeutics / Syntone Technologies) for . The deal was made on 04-Feb-2021.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Joint Venture (Outlook Therapeutics / Syntone Technologies) | 04-Feb-2021 | Joint Venture | Pharmaceuticals |
Outlook Therapeutics ESG
Risk Overview
Risk Rating
Updated March, 01, 2024
33.58 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile

Pharmaceuticals
Industry
of 853
Rank
Percentile

Biotechnology
Subindustry
of 368
Rank
Percentile

Outlook Therapeutics FAQs
-
When was Outlook Therapeutics founded?
Outlook Therapeutics was founded in 2010.
-
Where is Outlook Therapeutics headquartered?
Outlook Therapeutics is headquartered in Iselin, NJ.
-
What is the size of Outlook Therapeutics?
Outlook Therapeutics has 23 total employees.
-
What industry is Outlook Therapeutics in?
Outlook Therapeutics’s primary industry is Drug Discovery.
-
Is Outlook Therapeutics a private or public company?
Outlook Therapeutics is a Public company.
-
What is Outlook Therapeutics’s stock symbol?
The ticker symbol for Outlook Therapeutics is OTLK.
-
What is the current stock price of Outlook Therapeutics?
As of 07-Feb-2025 the stock price of Outlook Therapeutics is $1.71.
-
What is the current market cap of Outlook Therapeutics?
The current market capitalization of Outlook Therapeutics is $54.7M.
-
Who are Outlook Therapeutics’s competitors?
Apellis Pharmaceuticals, Opthea, Affimed, Henlius, and Immunocore Holdings are some of the 30 competitors of Outlook Therapeutics.
-
What is Outlook Therapeutics’s annual earnings per share (EPS)?
Outlook Therapeutics’s EPS for 12 months was -$4.06.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »